MAP2K7 and acute myeloid leukemia: NrasLSL-G12D; Cbfb56M leukemic cells were sensitive to pharmacologic inhibition of the MEK/ERK signaling pathway [192], highlighting the importance of this pathway in AML and proposing MEK inhibitors as potential therapeutic agents in inv16/ N-RASG12D AML [192].